USA Loretta Beine, Senior Director of Industry Development for Life Sciences, Empire State Development (ESD) explains the organization’s broader role in growing New York State’s life sciences sector beyond direct funding. As New York State’s chief economic development agency, ESD focuses on supporting startups, attracting new investment, and job creation to…
USA Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discusses how the company’s dual commercial pillars in Parkinson’s disease psychosis and Rett syndrome are delivering much-needed impact for patients with significant unmet needs and shaping Acadia’s next phase of growth. She shares insights into the company’s expansion plans, pipeline strategy, partnership goals,…
France MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and early scientific partnerships shaped a platform now approaching its first potential approval for its first microbiome drug candidate. The journey…
Taiwan Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech, she returned to Taiwan a decade ago and brought two companies to IPO on the Taipei stock exchange. She joined…
Taiwan PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren Wang outlines how ONIVYDE® provides the stability to advance a more ambitious pipeline, how a virtual model sharpens scientific focus…
Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…
France Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on the scientific foundations of RNAi, the strengths and pressures of the French rare-disease ecosystem, and the conditions needed to ensure…
France argenx has moved from an antibody engineering start-up to one of Europe’s most closely-watched biotechs, advancing a pipeline that spans multiple autoimmune diseases. In this interview, François Rauch reflects on argenx’ growing position in France, , the lessons drawn from navigating France’s evolving access landscape and the broader policy conditions…
China Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis and asthma. In this interview, Founder and CEO Dr Chenghai Zhang shares how a lean, discovery-driven model and a focus…
Taiwan With its thriving innovation ecosystem and growing global visibility, Taiwan is fast emerging as one of Asia’s most dynamic biotechnology hubs. At the forefront of this transformation is Wallace Lin, Secretary-General of Taiwan Bio, who has spent his career bridging science, policy, and industry to strengthen the nation’s life sciences…
Hong Kong After a challenging few years, the Hong Kong Stock Exchange (HKEX)’s IPO market bounced back strongly in 2025. By the end of Q3 2025, HK listings raised USD 23.9 billion across 66 IPOs (up 192 percent vs the previous year). Pre-revenue biotech listings, predominantly from mainland China, are also up…
Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…
See our Cookie Privacy Policy Here